Abstract: The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

Abstract: The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

Abstract: The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

Abstract: A drug-delivery cannula assembly includes a cannula housing adapted for receiving at least one obturator shaft of an obturator assembly therethrough, one or more cannulae, and a supply line coupled to the cannula housing. The cannula housing is adapted for receiving one or more obturator shafts of an obturator assembly therethrough. The one or more cannulae define a longitudinal axis and a passageway aligned with the longitudinal axis. The one or more cannulae each include a proximal end coupled to the cannula housing. The cannula housing is configured to fluidly-couple the one or more cannulae to a source of a drug delivery supply for supplying drugs via the supply line to the one or more cannulae.

Abstract: The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

Abstract: A drug-delivery device includes a body configured for attachment to a handle of an ablation device, a shaft portion defining a passageway therein, and a delivery lumen to provide for drug delivery to tissue. The body includes a proximal portion, a distal portion, and a contoured portion disposed therebetween. The contoured portion is configured for engagement with a contoured portion of the handle of the ablation device. The shaft portion includes a proximal end and a distal end. The proximal end of the shaft engages with an opening defined in the distal end of the body. The passageway of the shaft portion is configured to receive the delivery lumen slideably moveably therein. The delivery lumen includes a proximal portion and a distal portion. The drug-delivery device also includes a knob member coupled to the proximal portion of the delivery lumen.

Abstract: A drug-delivery device includes a body configured for attachment to a handle of an ablation device, a shaft portion defining a passageway therein, and a delivery lumen to provide for drug delivery to tissue. The body includes a proximal portion, a distal portion, and a contoured portion disposed therebetween. The contoured portion is configured for engagement with a contoured portion of the handle of the ablation device. The shaft portion includes a proximal end and a distal end. The proximal end of the shaft engages with an opening defined in the distal end of the body. The passageway of the shaft portion is configured to receive the delivery lumen slideably moveably therein. The delivery lumen includes a proximal portion and a distal portion. The drug-delivery device also includes a knob member coupled to the proximal portion of the delivery lumen.

Abstract: The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

Abstract: The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

Abstract: A drug-delivery device includes a body configured for attachment to a handle of an ablation device, a shaft portion defining a passageway therein, and a delivery lumen to provide for drug delivery to tissue. The body includes a proximal portion, a distal portion, and a contoured portion disposed therebetween. The contoured portion is configured for engagement with a contoured portion of the handle of the ablation device. The shaft portion includes a proximal end and a distal end. The proximal end of the shaft engages with an opening defined in the distal end of the body. The passageway of the shaft portion is configured to receive the delivery lumen slideably moveably therein. The delivery lumen includes a proximal portion and a distal portion. The drug-delivery device also includes a knob member coupled to the proximal portion of the delivery lumen.

Abstract: A drug-delivery cannula assembly includes a cannula housing adapted for receiving at least one obturator shaft of an obturator assembly therethrough, one or more cannulae, and a supply line coupled to the cannula housing. The cannula housing is adapted for receiving one or more obturator shafts of an obturator assembly therethrough. The one or more cannulae define a longitudinal axis and a passageway aligned with the longitudinal axis. The one or more cannulae each include a proximal end coupled to the cannula housing. The cannula housing is configured to fluidly-couple the one or more cannulae to a source of a drug delivery supply for supplying drugs via the supply line to the one or more cannulae.

Abstract: An ablation system includes a source of electrosurgical energy, a source of coolant fluid, and an ablation electrode assembly operatively connected to the source of electrosurgical energy and fluidly-coupled to the source of coolant fluid. The ablation electrode assembly includes a hub defining a chamber therein and one or more electrically-conductive ablation needles extending from the hub. The ablation system also includes one or more delivery needles extending from the hub. The one or more delivery needles are selectively moveable from a first position, wherein the distal end of the delivery needle is disposed proximal to the distal end portion of the ablation needle, to at least a second position, wherein at least the distal end of the delivery needle is disposed distally beyond the distal end portion of the ablation needle.

Abstract: An ablation device includes a handle assembly, an ablation electrode extending from the handle assembly, and one or more delivery needles extending from the handle assembly. The ablation electrode includes an ablation needle. The ablation needle includes a distal end portion including a drug delivery port defined therethrough. The ablation device also includes and a biopsy tool extending from the handle assembly.

Abstract: The invention provides lubricant compositions comprising magnesium stearate dihydrate. The lubricant compositions may be used to lubricate a variety of solid materials that are used in industrial or consumer products.

Abstract: An improved orally dissolving tablet (ODT) and method of manufacture is provided. The improved ODT disclosed herein are prepared by direct compression of a mixture of pharmaceutical excipients including at least one water-insoluble hydrophobic inorganic salt in combination with at least one water-insoluble inorganic salt with less hydrophobicity compared to the water-insoluble hydrophobic inorganic salt component. These components may be formed into granules, and may include other commonly used excipients. In an illustrative embodiment, the granules are formed into tablets by direct compression, optionally using a lubricant. The fast disintegrating tablets prepared using these components exhibit desirable performance properties such as sufficient hardness, low friability, quick disintegration time and good mouth-feel when compared to conventional ODT. A further advantage is that the improved ODT may be manufactured using commonly available manufacturing equipment for granulation, blending and tableting.

Abstract: The present invention is directed to improved compositions and methods for preparing orally disintegrating tablets (ODTs). In one aspect of the present invention, the ODT further contains at least one active pharmaceutical ingredient (API). In another aspect of the present invention, the ODT contains a high load of at least one API. Specifically, the ODTs described in this invention containing a high load of API can accommodate up to about 70% w/w of active pharmaceutical ingredient in a unit dosage, while exhibiting the desirable attributes of fast disintegration time, acceptable hardness and friability for push through blister and bottle packages, and acceptable mouth feel.

Abstract: The invention provides lubricant compositions comprising magnesium stearate dihydrate. The lubricant compositions may be used to lubricate a variety of bioactive formulations including pharmaceutical compositions.

Abstract: A method for converting polymorphs of Zolpidem hemitartrate, the method comprising treating tablets comprising Zolpidem hemitartrate with heat and/or moisture.

Abstract: Water dispersible polyester polymers, polyesteramides polymers and blends of these polymers are dispersed in water and spray dried to form fine powders. In the solid state, these powders can absorb oils and/or diffuse ambient light, thereby resulting in the production of significant reduction in gloss and tack of lipids in cosmetic and personal care products when applied to ordinarily oily skin.

Abstract: Provided is a process useful for preparing acrylic polymers of methacrylic acid and ethyl acrylate. The process provides polymers useful as enteric coatings for medicaments in solid form, said coatings having improved effectiveness, reproducibility and coating efficiency. Also provided are medicaments in solid form coated with such polymers.